Business

India’s Pharma Sector Powers Ahead in April 2025, Fueled by Price Gains and New Product Launches: Pharmatrack

This growth surge is primarily attributed to price-led expansion and the steady introduction of new products, indicating strategic pricing and innovation are playing key roles in propelling the industry forward.

• By Newsdesk
• New Delhi
• May 10, 2025

Business

India’s pharmaceutical industry continues to demonstrate remarkable resilience, clocking a robust 7.8% year-on-year growth in April 2025 with total monthly sales touching ₹19,711 crore. The latest data from Pharmatrack reveals an additional ₹1,424 crore in sales compared to last year, underscoring the sector’s sustained momentum amid evolving healthcare needs.

This growth surge is primarily attributed to price-led expansion and the steady introduction of new products, indicating strategic pricing and innovation are playing key roles in propelling the industry forward. On a moving annual total (MAT) basis, the sector now stands at ₹2,27,361 crore — reflecting an 8.3% increase over the previous year and a healthy 10.3% compound annual growth rate (CAGR).

Specialty and chronic therapy areas continue to anchor this growth. Therapeutic segments such as cardiac care, neurology/CNS, blood-related disorders, oncology, ophthalmology/otology, and urology showed strong traction in April, signaling the increasing medical emphasis on chronic disease management and complex care.

Despite overall volume growth being modest at 0.4%, the industry's strategic pricing mechanisms proved effective in navigating cost pressures and supporting top-line growth. Cardiac and anti-infective therapies stood out in volume expansion — the former driven by the continued demand for anti-hypertensives and heart health medications, and the latter spurred by seasonal ailments and localized outbreaks.

From a pricing standpoint, respiratory therapies recorded the steepest increase at 6.6%, followed closely by cardiac and gastrointestinal categories, reflecting market dynamics in these high-demand segments. Among emerging stars, stomatologicals — treatments related to oral health — saw a 7.7% boost, propelled by new product launches in specialized, underserved niches.

The April performance reaffirms the Indian pharma industry’s long-term growth trajectory, bolstered by strategic pricing, innovation, and a deepening focus on chronic and specialty care.